Lipegfilgrastim
Also known as: glycoPEG-G-CSF, GlycoPEGylated filgrastim, Lipegfilgrastim, Lonquex, XM22
Source Lipegfilgrastim at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Lipegfilgrastim is a long‑acting, glyco‑PEGylated form of filgrastim used to prevent febrile neutropenia in patients receiving myelosuppressive chemotherapy.
Mechanism of Action
Agonist of the G‑CSF receptor, stimulating proliferation, differentiation and activation of neutrophil precursors, thereby reducing chemotherapy‑induced neutropenia
Routes of Administration
Goals & Uses
- Prevention of chemotherapy‑induced neutropeniaOncology Supportive CareHigh
- Reduction of febrile neutropenia durationOncology Supportive CareHigh
- Reduction of infection risk during myelosuppressive chemotherapyOncology Supportive CareHigh
- Prevention of chemotherapy-induced neutropeniaOncology Supportive CareHigh
Contraindications
- Use in patients with chronic myeloid leukemia or myelodysplastic syndromeOncologyHigh
- Patients with known myeloid malignancies (e.g., chronic myeloid leukemia) not in remissionHematologicModerate
- Hypersensitivity to lipegfilgrastim or PEGylated G-CSF productsAllergy/immunologyHigh
- Hypersensitivity to lipegfilgrastim or any excipientAllergyHigh
Adverse Effects
- Acute respiratory distress syndrome (ARDS)PulmonaryRare
- Splenomegaly / splenic ruptureOrgan ToxicityRare
- Bone painMusculoskeletalCommon
- Injection site reactionsLocalCommon
- LeukocytosisHematologicCommon
- ThrombocytopeniaHematologicUncommonLow platelet count
- Splenic ruptureGastrointestinal/HematologicRare
- Injection‑site reactionsLocalCommon
- Bone pain / musculoskeletal painMusculoskeletalCommon
Drug Interactions
- Cytotoxic chemotherapy agentsHigh
- CorticosteroidsLow
- LithiumLow
- Concurrent myelosuppressive chemotherapyModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patients (under 18 years)AgeRelative
- Pediatric patientsAgeRelative
- Patients with sickle cell diseaseHematologic DisorderRelative
- Pregnant womenReproductiveRelative
- BreastfeedingReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Prevention of chemotherapy‑induced neutropeniaMarketed as Lonquex.
- RUApprovedApproved: Prevention of chemotherapy‑induced neutropeniaApproved under local brand names.
- United StatesUnapprovedNot submitted for FDA approval; pegfilgrastim is the FDA‑approved counterpart.
- United KingdomApprovedApproved: Reduction in duration of severe neutropenia and incidence of febrile neutropenia in adult cancer patients receiving cytotoxic chemotherapyApproved via EMA decision prior to Brexit; status maintained post-Brexit through MHRA
Approved in the European Union (brand Lonquex) and several other jurisdictions; not approved by the US FDA.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Lipegfilgrastim?
Lipegfilgrastim is a long‑acting, glyco‑PEGylated form of filgrastim used to prevent febrile neutropenia in patients receiving myelosuppressive chemotherapy.
What is Lipegfilgrastim used for?
Lipegfilgrastim is educationally associated with: Prevention of chemotherapy‑induced neutropenia, Reduction of febrile neutropenia duration, Reduction of infection risk during myelosuppressive chemotherapy, Prevention of chemotherapy-induced neutropenia. Educational only — not medical advice.
How is Lipegfilgrastim administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Lipegfilgrastim?
Reported adverse effects include: Acute respiratory distress syndrome (ARDS), Splenomegaly / splenic rupture, Bone pain, Injection site reactions, Leukocytosis, Thrombocytopenia, Splenic rupture, Injection‑site reactions, Bone pain / musculoskeletal pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Lipegfilgrastim?
Recorded contraindications: Use in patients with chronic myeloid leukemia or myelodysplastic syndrome, Patients with known myeloid malignancies (e.g., chronic myeloid leukemia) not in remission, Hypersensitivity to lipegfilgrastim or PEGylated G-CSF products, Hypersensitivity to lipegfilgrastim or any excipient. Consult a qualified clinician before use.